Articles with public access mandates - Antonio CostanzoLearn more
Not available anywhere: 10
Pharmacogenetics of psoriasis: HLA‐Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker …
M Talamonti, E Botti, M Galluzzo, M Teoli, G Spallone, M Bavetta, ...
British Journal of Dermatology 169 (2), 458-463, 2013
Mandates: Government of Italy
Role of the HLA‐C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients
M Talamonti, M Galluzzo, JM Van Den Reek, EM de Jong, JLW Lambert, ...
British Journal of Dermatology 177 (2), 489-496, 2017
Mandates: European Commission, Government of Italy
Secukinumab shows high efficacy irrespective of HLA‐Cw6 status in patients with moderate‐to‐severe plaque‐type psoriasis: results from extension phase of the …
M Papini, F Cusano, M Romanelli, M Burlando, G Stinco, G Girolomoni, ...
British Journal of Dermatology 181 (2), 413-414, 2019
Mandates: European Commission, Government of Italy
Sox2 is not required for melanomagenesis, melanoma growth and melanoma metastasis in vivo
V Cesarini, E Guida, F Todaro, S Di Agostino, V Tassinari, S Nicolis, ...
Oncogene 36 (31), 4508-4515, 2017
Mandates: Government of Italy
The mechanistic basis for psoriasis immunopathogenesis: translating genotype to phenotype. Report of a workshop, Venice, 2012
H Bachelez, M Viguier, PW Tebbey, M Lowes, M Suárez‐Fariñas, ...
British Journal of Dermatology 169 (2), 283-286, 2013
Mandates: UK Medical Research Council
Potential role of HLA-Cw6 in clinical response to anti-tumour necrosis factor alpha and T-cell targeting agents in psoriasis patients
M Talamonti, M Galluzzo, E Botti, A Pavlidis, G Spallone, S Chimenti, ...
Clinical Drug Investigation 33 (2), S71, 2013
Mandates: Government of Italy
649-Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials
K Reich, RG Langley, JF Silvestre, D Staumont-Salle, A Costanzo, A Pink, ...
British Journal of Dermatology 191 (Supplement_2), ljae266. 028, 2024
Mandates: National Institute for Health Research, UK
555-Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials
K Reich, RG Langley, JF Silvestre, D Staumont-Salle, A Costanzo, A Pink, ...
British Journal of Dermatology 190 (Supplement_2), ii52-ii53, 2024
Mandates: National Institute for Health Research, UK
15. Long-term Improvements in Disease Severity, Itch, and Quality of Life after 3 Years of Tralokinumab Treatment in Adults with Moderate-to-severe Atopic Dermatitis
R Langley, K Reich, E Simpson, RB Warren, A Costanzo, H Saeki, ...
Journal of Dermatology for Physician Assistants 16 (4), 55-57, 2022
Mandates: Swedish Council for Health, Labor and Welfare
Etanercept Reverses Downregulation of Inhibitor of Nuclear Factor Kappa-B Kinase Subunit Alpha (IKK [alpha]) in Psoriasis
G Spallone, E Botti, V Pinetti, M Bavetta, A Pavlidis, S Chimenti, ...
Clinical Drug Investigation 33 (2), S69, 2013
Mandates: Government of Italy
Available somewhere: 39
Developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas
E Botti, G Spallone, F Moretti, B Marinari, V Pinetti, S Galanti, ...
Proceedings of the National Academy of Sciences 108 (33), 13710-13715, 2011
Mandates: US National Institutes of Health
Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries
SR Knight, CA Shaw, R Pius, TM Drake, L Norman, AO Ademuyiwa, ...
The Lancet 397 (10272), 387-397, 2021
Mandates: US National Institutes of Health, National Institute for Health Research, UK …
p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis
RN Matin, A Chikh, S Law Pak Chong, D Mesher, M Graf, P Sanza’, ...
Journal of Experimental Medicine 210 (3), 581-603, 2013
Mandates: Cancer Research UK
The tumor suppressor activity of IKKα in stratified epithelia is exerted in part via the TGF-β antiproliferative pathway
B Marinari, F Moretti, E Botti, ML Giustizieri, P Descargues, A Giunta, ...
Proceedings of the National Academy of Sciences 105 (44), 17091-17096, 2008
Mandates: US National Institutes of Health
Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience
P Gisondi, S Piaserico, L Naldi, P Dapavo, A Conti, P Malagoli, ...
Journal of Allergy and Clinical Immunology 147 (2), 558-560. e1, 2021
Mandates: Fondazione Cariplo
γδ T cells are reduced and rendered unresponsive by hyperglycemia and chronic TNFα in mouse models of obesity and metabolic disease
KR Taylor, RE Mills, AE Costanzo, JM Jameson
PloS one 5 (7), e11422, 2010
Mandates: US National Institutes of Health
IL12B (p40) gene polymorphisms contribute to ustekinumab response prediction in psoriasis
M Galluzzo, AN Boca, E Botti, C Potenza, G Malara, P Malagoli, S Vesa, ...
Dermatology 232 (2), 230-236, 2016
Mandates: Government of Italy
IKKα is a p63 transcriptional target involved in the pathogenesis of ectodermal dysplasias
B Marinari, C Ballaro, MI Koster, ML Giustizieri, F Moretti, F Crosti, ...
Journal of investigative dermatology 129 (1), 60-69, 2009
Mandates: US National Institutes of Health
Secukinumab shows high efficacy irrespective of HLA‐Cw6 status in patients with moderate‐to‐severe plaque‐type psoriasis: SUPREME study
A Costanzo, L Bianchi, ML Flori, G Malara, L Stingeni, M Bartezaghi, ...
British journal of dermatology 179 (5), 1072-1080, 2018
Mandates: European Commission, Government of Italy
A role for the mevalonate pathway in the induction of subtype cross-reactive immunity to influenza A virus by human γδ T lymphocytes
JM Jameson, J Cruz, A Costanzo, M Terajima, FA Ennis
Cellular immunology 264 (1), 71-77, 2010
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program